Press Releases for IMCL

Press Releases
NASDAQ OMX and Leerink Swann to Co-Host Healthcare Industry Forum - Nov 25 2008 11:22AM
Lilly Completes Cash Tender Offer for ImClone Systems
ImClone Systems’ State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
Randomized Phase 2 Study of IMC-A12 for HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
ImClone Systems Announces Clearance of Tender Offer by German Federal Cartel Office
Phase 2 Study of IMC-1121B in First-Line Treatment of Advanced Non-Small Cell Lung Cancer Commences Patient Enrollment
ImClone Systems Announces Expiration of Hart-Scott-Rodino Waiting Period
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Zacks Analyst Blog Highlights: Bristol-Myers Squibb Co., ImClone Systems Inc., LSI Corp, Infineon Technologies A.G. And ConocoPhillips. - Oct 7 2008 12:18PM
ImClone Announces Merger Agreement with Eli Lilly at $70 Per Share
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
ImClone Systems Issues Statement - Oct 1 2008 10:01PM
Phase 2 Study of IMC-1121B for Advanced Ovarian Cancer Commences Patient Enrollment
ImClone Systems Issues Statement - Sep 29 2008 9:37AM
Randomized Phase 2 Study of IMC-A12 for Advanced Breast Cancer Commences Patient Enrollment
Icahn Responds to Cornelius
Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share
ERBITUX(R) Five-Year Data Show Significant Improvement in Overall Survival for Patients with Locally or Regionally Advanced Head and Neck Cancer
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
ImClone Systems Submits Letter to Bristol-Myers Squibb
Study Published in New England Journal of Medicine Shows ERBITUX(R) Improved Survival in First-Line Recurrent And/Or Metastatic Head and Neck Cancer
ImClone Systems Issues Statement - Sep 10 2008 9:03AM
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Zacks Analyst Interview Highlights: Genentech, ImClone Systems, Bristol-Myers Squibb and Celgene
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
Global Phase 3 Study of IMC-1121B in Metastatic Breast Cancer Commences
ImClone Systems Issues Statement - Aug 4 2008 9:29AM
ImClone Systems Issues Statement - Jul 31 2008 5:06PM
Smallcap-Investors.Com Morning Movers: QUIN, VIPR, IMCL, QMNM
ImClone Systems Reports Second Quarter 2008 Financial Results
ImClone Systems to Host Second Quarter 2008 Financial Results Conference Call
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
ImClone Announces Changes in Commercial Organization Leadership
Phase 2 Study Of IMC-A12 for Advanced Soft Tissue Sarcoma Opens for Patient Enrollment
IMC-A12 Plus Temsirolimus Clinical Trial for Advanced Cancer Opens for Patient Enrollment
ImClone Systems to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
New Analyst Reports for OSI PHARMACEUTICALS INC, CITRIX SYSTEMS INC, AMYLIN PHARMACEUTICALS INC, and IMCLONE SYSTEMS INCORPORATED
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
RTOG Study: Adding Cetuximab to Chemotherapy and Radiotherapy Leads to Improved Outcome for Lung Cancer Patients
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
ImClone to Host Investor Reception on June 1, 2008 to Discuss Data Presented at the American Society of Clinical Oncology Annual Meeting
Phase I/II Studies of IMC-A12 in Pancreatic Cancer Open for Patient Enrollment - May 27 2008 12:57AM
ImClone Systems to Present at the 2008 Citi Investment Research Global Health Care Conference - May 27 2008 12:56AM
Significant Data on ERBITUX(R) (cetuximab) and ImClone Pipeline to Be Presented at American Society of Clinical Oncology 2008 Annual Meeting - May 27 2008 12:55AM
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting - May 27 2008 12:55AM
Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment - Jun 1 2008 11:06PM
BellwetherReport.com Analyst Report on AHCI, CCOI, IMCL and WHRT - May 27 2008 1:20AM
Seven Summits Research Releases Comments on C, VLO, FDX, IMCL, and MELI - May 27 2008 1:20AM
ImClone Systems to Present at the Bank of America 2008 Healthcare Conference - Jun 1 2008 11:06PM
ImClone Systems Reports First Quarter 2008 Financial Results
ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
ImClone Systems to Host First Quarter 2008 Financial Results Conference Call
Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient Enrollment